Viral Vector and Plasmid DNA Manufacturing Market By Product Type (Plasmid DNA, Viral Vectors, and Non-viral Vectors), By Application (Cancer, Inherited Disorder, Infectious Diseases, and Other Applications), and By Region - Trends, Analysis and Forecast till 2030

Report Code: PMI381720 | Publish Date: May 2024 | No. of Pages: 180

Global Viral Vector And Plasmid Overview

Viral Vector and Plasmid DNA Manufacturing Market accounted for USD 2.5 Billion in 2020 and is estimated to be USD 9.49 Billion by 2030 and is anticipated to register a CAGR of 14.2%

Viral vectors and plasmid DNA are used in gene therapy. It is used to treat various diseases, such as Parkinson's disease, Alzheimer's disease, cancer, and other diseases. Gene therapies and other therapies that need genetic modification include the introduction of therapeutic DNA/gene in the patient's cell or body. This process is proficient by the use of viral vectors. In the past few years, different non-viral and viral vectors have been standardized and developed for the treatment purpose. Besides this, the viral vectors and plasmid DNAs are anticipated to decrease the repetitive administration of medications.

Global Viral Vector And Plasmid Drivers & Restraints

The increasing number of cancer patients drives the growth of the viral vector and plasmid DNA manufacturing market globally. Viral vectors and plasmid DNA are used to treat diseases such as cancer and various other diseases globally. For instance, according to the WHO (World Health Organization), in 2018, globally, cancer is the second most leading cause of death, an estimated 9.6 million deaths. Additionally, the technological advancement in the production of a viral vector to take care of patients which are another driving factor for the growth of the target market. Furthermore, the rise in the number of clinical trials of viral vector and plasmid DNA for better treatment is the fueling factor for the growth of the global market. Moreover, there is the rapid development of clinical trial phases due to growing numbers of candidates for the use of viral vector and plasmid DNA which is the boosting factor for the growth of the target market. However, the gene therapies are expensive treatment which is the major restraining factor for the growth of the target market.

Global Viral Vector And Plasmid Segmentations & Regional Insights

Viral vector and plasmid DNA manufacturing market are segmented based on product type, application, and region.

Based on product type, the viral vector and plasmid DNA manufacturing market are segmented into plasmid DNA, viral vectors, and non-viral vectors. The viral vectors are estimated the more revenue generator in the target market. Based on the application, the target market is segmented into cancer, inherited disorder, infectious diseases, and other applications. As there is an increasing number of cancer patients, cancer is the dominating segment for the growth of the global market.  

Regional Insights:  

Based on the region the viral vector and plasmid DNA manufacturing market are segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The global market in the North America region is seen to have a matured growth since this market correlates with the increasing growth rate of viral vector and plasmid DNA manufacturing. In the North America region, the increasing awareness about gene therapy is driving the growth of the global market in this region. Moreover, investments into research and development for better healthcare is anticipated to create growth opportunities for the Europe region viral vector and plasmid DNA manufacturing market over the forecast period.

Viral Vector and Plasmid DNA Manufacturing Market, By Product Type:

  • Plasmid DNA
  • Viral Vectors
  • Non-viral vectors

Viral Vector and Plasmid DNA Manufacturing Market, By Application:

  • Cancer
  • Inherited Disorder
  • Infectious Diseases
  • Other Applications

Viral Vector and Plasmid DNA Manufacturing Market, By Region:

  • North America
    • North America Viral Vector and Plasmid DNA Manufacturing Market, By Product Type
    • North America Viral Vector and Plasmid DNA Manufacturing Market, By Application
    • North America Viral Vector and Plasmid DNA Manufacturing Market, By Country
    • The U.S.
    • Canada
      • Europe
    • Europe Viral Vector and Plasmid DNA Manufacturing Market, By Product Type
    • Europe Viral Vector and Plasmid DNA Manufacturing Market, By Application
    • Europe Viral Vector and Plasmid DNA Manufacturing Market, By Country
    • Germany
    • UK
    • France
    • Russia
    • Italy
    • Rest of Europe
      • Asia Pacific
    • Asia Pacific Viral Vector and Plasmid DNA Manufacturing Market, By Product Type
    • Asia Pacific Viral Vector and Plasmid DNA Manufacturing Market, By Application
    • Asia Pacific Viral Vector and Plasmid DNA Manufacturing Market, By Country
      • China
      • India
      • Japan
      • South Korea
      • Rest of Asia Pacific
      • Latin America
    • Latin America Viral Vector and Plasmid DNA Manufacturing Market, By Product Type
    • Latin America Viral Vector and Plasmid DNA Manufacturing Market, By Application
    • Latin America Viral Vector and Plasmid DNA Manufacturing Market, By Country
      • Brazil
      • Rest of Latin America
      • Mexico
  • Middle East & Africa
  • Middle East & Africa Viral Vector and Plasmid DNA Manufacturing Market, By Product Type
  • Middle East & Africa Viral Vector and Plasmid DNA Manufacturing Market, By Application
  • Middle East & Africa Viral Vector and Plasmid DNA Manufacturing Market, By Country
    • GCC
    • Rest of Middle East & Africa
    • South Africa
    • Israel

Global Viral Vector And Plasmid Competitive Landscape & Key Players

The key players operating the viral vector and plasmid DNA manufacturing market involves Unique NV, Cell and Gene Therapy Catapult, FinVector Vision Therapies, Fujifilm Holdings Corporation (Fujifilm Diosynth Biotechnologies), Mass Biologics, SIRION Biotech, Cobra Biologics, Merck KGaA, Oxford Biomedica PLC, Thermo Fisher Scientific Inc. and Gilead Company. Prominent players operating in the target market are focusing on strategic partnerships as well as the launching of the product types to gain a competitive edge in the target market. In 2017, the retrovirus- based CAR-T cell immunotherapy developed in Gilead Company, was approved by the FDA.

Global Viral Vector And Plasmid Company Profile

  • Uniqure NV 
  • Cell and Gene Therapy Catapult
  • FinVector Vision Therapies
  • Fujifilm Holdings Corporation (Fujifilm Diosynth Biotechnologies)
  • MassBiologics
  • SIRION Biotech
  • Cobro Biologics
  • Merck KGaA
  • Oxford Biomedica PLC
  • Thermo Fisher Scientific Inc.
  • Gilead Company

FAQs

The global viral vector and plasmid DNA manufacturing market are segmented based on product type, application, and region.

The increasing number of cancer patients drives the growth of the global viral vector and plasmid DNA manufacturing market globally.

The global market in the North America region is seen to have a matured growth since this market correlates with the increasing growth rate of viral vector and plasmid DNA manufacturing.

Prominent players operating in the target market are focusing on strategic partnerships as well as the launching of the product types to gain a competitive edge in the target market. In 2017, the retrovirus- based CAR-T cell immunotherapy developed in Gilead Company, was approved by the FDA.